The FDA just approved Lecanemab: What you need to know about the Alzheimer's drug

Alzheimer's drug Leqembi, the first medicine shown to slow the disease, has earned FDA approval. Learn more about the treatment and what this means for patients  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  HEALTH NEWS Jul 10, 2023 The FDA just approved Lecanemab: What you need to know about the Alzheimer's drug Alzheimer's drug Leqembi, the first medicine shown to slow the disease, has earned FDA approval. Learn more about the treatment and what this means for patients More » TOP STORIES The FDA is being asked to look into Logan Paul's energy drink, which has the caffeine of 6 Coke cans » Short sleep negates benefits of exercise for the brain, study says » Disgraced sports doctor Larry Nassar stabbed multiple times in federal prison, AP sources say » President Biden and King Charles III zero in on climate change in Windsor Castle meeting » MORE STORIES Omaha Police: Law enforcement shoot and kill a murder suspect after a high speed chase » 1 dead, 3 hurt in Dubuque mass shooting » Iowa National Guard unveils 14,000-pound military vehicle » You're a winner! Iowa's biggest lottery jackpot winners » MANAGE YOUR ACCOUNT If you'd like to receive some of our other email newsletters, you can tap or click the links below: Be among the first to receive National Breaking News or Local Breaking News as stories break. Catch up on the day's big stories with our Morning Headlines and Afternoon Digest newsletters. Receive our Daily Forecasts or get Severe Weather Alerts sent straight to your email inbox. Manage your email newsletter subscriptions » For the very latest information, download our free apps To ensure email delivery, add newsletters@e.kcci.com to your address book or safe senders list © 2023 Hearst Television Inc. 300 W 57th Street, New York NY 10019 Privacy Notice | Terms of Use | Unsubscribe